Labiotech.eu

News and Trends 14 May 2015

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. Cancers figure […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 May 2015

Selecta continues its tour around France with another collaboration

Selecta Biosciences and Généthon are collaborating to enable repeat dosing for gene therapies. The companies are combining Généthon’s expertise in the development of gene therapy vectors and Selecta’s Synthetic Vaccine Particle platform to prevent undesired immune responses. Selecta seems quite fond of collaborating with French companies. After allying with Sanofi, the US-based company has announced […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 May 2015

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Sanofi and Selecta Biosciences are going to extend their three-year-old partnership to develop an immunotherapy for the treatment of celiac disease. Selecta may receive €264M from the biggest French Pharma company, in terms of research support and sales milestones. The two companies are now collaborating on three programs for immune tolerance. In celiac disease patients, […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 May 2015

Syngenta rejects Monsanto’s €40-Billion takeover offer

Syngenta has rejected Monsanto‘s merger proposal… again. The American colossus made an offer that Syngenta declined, as the Swiss crop developer considered that Monsanto’s €40Bn bid (CHF 41.7 billion) simply was not enough. The gossip started last week as Monsanto may have done a second attempt to buy Swiss Syngenta. Turns out, the rumors were true, but the negotiations lead […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 May 2015

Axovant banks on GSK’s scrapped project

Last December, Axovant acquired for €4.5M ($5 million) the drug candidate SB742457 from GlaxoSmithKline. Four months later, the company announced its initial public offering to raise up to €154M ($173 million). Why is this newly funded company betting on the leftovers of the Big Pharma? The drug candidate SB742457 is a selective 5-HT6 receptor antagonist, developed as an oral […]

May 13, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 13 May 2015

[UPDATE] Adaptimmune raised €156.7M in its IPO

Oxford-based Adaptimmune has launched its IPO on NASDAQ, where the immunotherapist plans to raise about €156.7M. The company is focused on novel cancer immunotherapy products based on T-cell receptors. [UPDATE]: The company successfully raised the quantity expected. Adaptimmune is focused on the use of T-cell therapy to treat cancer. It aims to utilise the body’s own machinery, T […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 May 2015

Alexion will invest €450 million to expand to Dublin

Alexion Pharmaceuticals will travel across the ocean to build its first ever biologics manufacturing facility outside the United States. This €450 million, four-year project, will be constructed at the Alexion’s College Park site in Blanchardstown (Ireland) and should create approximately 200 additional full-time jobs. This will bring Alexion’s total workforce in Ireland to almost 500 employees. […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 May 2015

US-based Juno Therapeutics purchased a German biotech

Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich and Göttingen, Germany. The acquired technologies will support the development of the next generation CAR-T and TCR-T products, bringing Juno one step closer to beating cancer. The transaction further underlines Juno’s strategy of becoming a world leader in process development and in […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Cambridge-based PhoreMost has been selected to receive a funding award of €1.96M (£1.4 million) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers. The British company that aims to provide low-priced and more diversed therapeutics, has developed ‘Site-Seeker’, a next-generation phenotypic screening platform based on PhoreMost’s Protein […]

May 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 May 2015

Ecrins Therapeutics’ first fundraising entirely crowdfunded by WiSEED

Ecrins Therapeutics, the company we interviewed last week, has successfully finished its first crowdfunding fundraiser, reaching €535k on WiSEED’s platform. The capital will allow the company to launch the large-scale chemical synthesis and regulatory toxicology studies, essential groundwork for the start of clinical Phase I/IIa. A second fundraise is already programmed in 2016 to finance […]

May 11, 2015 - 4 minutesmins - By Marie Godar

News and Trends 11 May 2015

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Ten years ago, Galapagos completed its initial public offering with a dual listing in Amsterdam and Brussels. Since then, Galapagos has grown, from 70 to more than 400 employees and from €70M to around €1.2Bn in market capitalization. Galapagos recently reported positive results with its JAK1 inhibitor in nearly 900 rheumatoid arthritis patients worldwide, triggering the interest […]

May 11, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 10 May 2015

Succesful Phase III for Indivior’s Schizophrenia treatment

Indivior obtained top-line results from its phase III clinical trial of RBP-7000, a candidate treatment for schizophrenia. Based on these successful outcomes, the company expects to submit a New Drug Application to the U.S. FDA for potential approval in 2017. Schizophrenia is a chronic, severe and disabling brain disorder that affects an estimated 26 million […]

May 10, 2015 - 1 minutemin - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Selecta continues its tour around France with another collaboration

Sanofi and Selecta will develop a “Negative Vaccine” for Celiac Disease

Syngenta rejects Monsanto’s €40-Billion takeover offer

Axovant banks on GSK’s scrapped project

[UPDATE] Adaptimmune raised €156.7M in its IPO

Alexion will invest €450 million to expand to Dublin

US-based Juno Therapeutics purchased a German biotech

PhoreMost awarded €1.96M to target the “undruggable” Cancer Genes

Ecrins Therapeutics’ first fundraising entirely crowdfunded by WiSEED

Are AbbVie and J&J already fighting to acquire Galapagos’ pipeline?

Succesful Phase III for Indivior’s Schizophrenia treatment

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!